Radiolabelled Trastuzumab PET/CT imaging: a promising non-invasive tool for the in vivo assessment of HER2 status in breast cancer patients

ConclusionAdditional studies are needed to validate the potential role of radiolabelled trastuzumab PET/CT, demonstrating its effectiveness in detection of HER2-positive lesions and in identification of BC patients who could benefit from specific and personalized therapy.

Source: Clinical and Translational Imaging - March 17, 2020 Category: Radiology Source Type: research